Plasma Rich in Growth Factor (PRGF) Therapy for Endometrial Receptivity: A Promising Approach in In vitro Fertilization (IVF) for Infertility with Uterine Polyps

This case study involved a 28-year-old woman with primary infertility, chronic abnormal vaginal bleeding, recurrent miscarriages, and uterine polyps. After undergoing hysteroscopic polypectomy to remove the polyps, plasma rich in growth factors <b>(</b>PRGF) therapy was administered to enhance endometrial thickness. Following the therapy, the endometrial thickness increased to 7 mm, leading to successful implantation and a positive pregnancy outcome. PRGF therapy was integrated into the <i>in vitro</i> fertilization (IVF) process, including ovum pickup, intracytoplasmic sperm injection (ICSI), and embryo transfer. PRGF releases growth factors, such as platelet-derived growth factor and transformation growth factor (TGF-β1), which play key roles in repairing endometrial tissue, promoting cell proliferation, and enhancing the function of primary cells involved in tissue regeneration. Although the short-term results in this case are promising, further research is necessary to investigate the long-term effects of PRGF therapy on IVF outcomes, including implantation success, biochemical pregnancies, and ongoing pregnancies. PRGF therapy shows promise as a complementary treatment in IVF protocols, particularly for patients with thin endometrial linings or uterine polyps. It offers a safe, minimally invasive, and cost-effective approach to improving endometrial receptivity and enhancing IVF success rates. However, further studies are needed to validate its long-term efficacy and its role in improving overall reproductive outcomes.